Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human 4-1BB Protein, Fc Tag, 100µg  

Recombinant human 4-1BB Protein, Fc Tag, 100µg

Recombinant Human 4-1BB / TNFRSF9 Protein, Gln 25 - Gln 186, produced in human 293 cells (HEK293), Fc Tag (MALS verified)

Synonym
recomninant, human protein, TNFRSF9, 4-1BB, CD137, CDw137, ILA

More details

41B-H5258-100

Availability: within 7 days

348,00 €

Background
4-1BB, also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

Source
Recombinant Human 4-1BB, Fc Tag (41B-H5258) is expressed from human 293 cells (HEK293). It contains AA Leu 24 - Gln 186 (Accession # NP_001552.2).
Predicted N-terminus: Leu 24

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 43.4 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Expansion of CD3+CD8+PD1+ T lymphocytes and TCR repertoire diversity predict clinical responses to adoptive cell therapy in advanced gastric cancer"
Wang, Shi, Zhao et al
Am J Cancer Res (2022) 12 (5), 2203-2215
(2) "DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity"
Muik, Adams Iii, Gieseke et al
J Immunother Cancer (2022) 10 (6)
(3) "[Preparation of CD52-targeted chimeric antigen receptor-modified T cells and their anti-leukemia effects]"
Liu, Liu, Tang et al
Zhonghua Xue Ye Xue Za Zhi (2022) 43 (4), 279-286
Showing 1-3 of 1519 papers.